Daiichi Sankyo Still Faces Claims Over Injectable Anemia Drug

Daiichi Sankyo Co. and its unit American Regent Inc. must keep defending a woman’s suit alleging an injectable iron deficiency anemia drug caused a serious blood chemistry imbalance, after the Eastern District of Pennsylvania rejected its preemption arguments.

Katherine Crockett alleges Injectafer caused her severe hypophosphatemia, a low blood phosphate level, which led to pain, weakness, and constant fatigue.

Daiichi and American Regent failed to show that federal drug labeling law preempts Crockett’s state-law claims alleging inadequate warning and design defect, the U.S. District Court for the Eastern District of Pennsylvania said.

The drugmakers argued that Crockett’s claims are barred ...